Save information for later
Sign Up

Learn About Macular Corneal Dystrophy Type 1

What is the definition of Macular Corneal Dystrophy Type 1?
Macular corneal dystrophy (MCD-1) type 1 is a rare, severe eye disease characterized by a cloudy, irregular covering over the cornea (outer covering of the eye), also known as a stromal corneal dystrophy.
What are the symptoms of Macular Corneal Dystrophy Type 1?
Symptoms of macular corneal dystrophy type 1 include a progressive whitish opacity that clouds the covering of the eye (cornea) which eventually causes severe visual impairment.
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Macular Corneal Dystrophy Type 1?
Treatment for macular corneal dystrophy type 1 includes corneal grafting or corneal transplantation.
Who are the top Macular Corneal Dystrophy Type 1 Local Doctors?
John D. Gottsch
Elite in Macular Corneal Dystrophy Type 1
Ophthalmology
Elite in Macular Corneal Dystrophy Type 1
Ophthalmology

The Johns Hopkins Hospital

1800 Orleans Street, 
Baltimore, MD 
Languages Spoken:
English

John D. Gottsch, M.D., is the Margaret C. Mosher Professor of Ophthalmology at the Wilmer Eye Institute. Dr. Gottsch specializes in the management of hereditary corneal disorders such as Fuchs' dystrophy, the surgical treatment of cataract and complications of cataract surgery, and corneal transplantation surgery. His clinical practice involves the medical treatment of allergic eye diseases and severe corneal inflammation from rheumatoid and other related disorders, including Mooren''s ulcer. His research interests include determining the gene expression of the cornea and the genetic basis for hereditary corneal diseases such as Fuchs' dystrophy. Dr. Gottsch is rated as an Elite provider by MediFind in the treatment of Macular Corneal Dystrophy Type 1. His top areas of expertise are Macular Corneal Dystrophy Type 1, Fuchs Dystrophy, Corneal Dystrophy and Perceptive Deafness, Cataract, and Corneal Transplant.

Allen Eghrari
Elite in Macular Corneal Dystrophy Type 1
Ophthalmology
Elite in Macular Corneal Dystrophy Type 1
Ophthalmology

The Johns Hopkins Hospital

1800 Orleans Street, Maumenee Lobby, Maumenee Lobby, 
Baltimore, MD 
Languages Spoken:
English

Allen O. Eghrari, M.D., M.P.H., is director of the Dana Center for Preventive Ophthalmology at the Wilmer Eye Institute and associate professor of ophthalmology at the Johns Hopkins University School of Medicine. He specializes in cornea, cataract and external eye diseases at the Wilmer Eye Institute's locations in Baltimore and Belcamp, Maryland. Dr. Eghrari treats a wide range of eye conditions, with special interest in Fuchs' dystrophy, cataract surgery, cornea transplantation including Descemet Membrane Endothelial Keratoplasty, and Ebola-associated eye disease. Dr. Eghrari received his M.D. degree from the Johns Hopkins University School of Medicine and M.P.H. from the Johns Hopkins Bloomberg School of Public Health. He completed both residency training in ophthalmology and subspecialty fellowship in cornea and cataract surgery at the Wilmer Eye Institute. Dr. Eghrari is a recipient of the Claes Dohlman Society Fellowship Award, the ARVO/Alcon Early Career Clinician-Scientist Award, and the Research to Prevent Blindness Special Scholar Award. Dr. Eghrari is rated as an Elite provider by MediFind in the treatment of Macular Corneal Dystrophy Type 1. His top areas of expertise are Fuchs Dystrophy, Macular Corneal Dystrophy Type 1, Cataract, Corneal Transplant, and Cataract Removal.

 
 
 
 
Learn about our expert tiers
Learn More
Terry Kim
Distinguished in Macular Corneal Dystrophy Type 1
Ophthalmology
Distinguished in Macular Corneal Dystrophy Type 1
Ophthalmology

Davis Ambulatory Surgical Center

120 E Carver St, 
Durham, NC 
Languages Spoken:
English
Accepting New Patients
Offers Telehealth

Terry Kim is an Ophthalmologist in Durham, North Carolina. Dr. Kim is rated as a Distinguished provider by MediFind in the treatment of Macular Corneal Dystrophy Type 1. His top areas of expertise are Corneal Dystrophy and Perceptive Deafness, Macular Corneal Dystrophy Type 1, Fuchs Dystrophy, and Cataract. Dr. Kim is currently accepting new patients.

What are the latest Macular Corneal Dystrophy Type 1 Clinical Trials?
Targeting Reactive Oxygen Species Production as a Novel Therapeutic in Fuch's Endothelial Corneal Dystrophy

Summary: This protocol will investigate whether topical application of N-acetyl cysteine (NAC) eye drops decreases oxidative stress and confers cytoprotection in patients with FECD.

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 2, Multicenter, Open-Label Study to Assess the Pharmacodynamics, Safety, and Tolerability of DT-168 Ophthalmic Solution in Patients With Fuchs Endothelial Corneal Dystrophy Undergoing Keratoplasty

Summary: The purpose of this study is to evaluate the pharmacodynamics, safety, and tolerability of DT-168 Ophthalmic Solution in pre-keratoplasty patients with Fuchs endothelial corneal dystrophy.